Nateglinide

From Wikipedia, the free encyclopedia

Nateglinide
Systematic (IUPAC) name
3-phenyl-2-(4-propan-2-ylcyclohexyl) carbonylamino-propanoic acid
Identifiers
CAS number	105816-04-4
ATC code	A10BX03
PubChem	60026
DrugBank	APRD00593
Chemical data
Formula	C19H27NO3
Mol. mass	317.423 g/mol
Pharmacokinetic data
Bioavailability	?
Protein binding	98%
Metabolism	?
Half life	1.5 hours
Excretion	?
Therapeutic considerations
Licence data	EU, US
Pregnancy cat.	?
Legal status
Routes	?

Nateglinide (INN, trade name Starlix) is a drug for the treatment of type 2 diabetes. Nateglinide was developed by the Swiss pharmaceutical company Novartis.

Nateglinide belongs to the meglitinide class of blood glucose-lowering drugs.

[edit] Pharmacology

Nateglinide lowers blood glucose by stimulating the release of insulin from the pancreas. It achieves this by closing ATP-dependent potassium channels in the membrane of the β cells. This depolarizes the β cells and causes voltage-gated calcium channels to open. The resulting calcium influx induces fusion of insulin-containing vesicles with the cell membrane, and insulin secretion occurs.

[edit] Dosage

Nateglinide is delivered in 60mg & 120mg tablet form.

[edit] External links

• Starlix - website of the manufacturer.
• How Nateglinide Works - website of the manufacturer.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10) Biguanides Metformin Sulfonylureas Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide Alpha-glucosidase inhibitors Acarbose, Miglitol, Voglibose Thiazolidinediones (TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ Meglitinides Nateglinide, Repaglinide, Mitiglinide Dipeptidyl peptidase-4 (DPP-4) inhibitors Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin Glucagon-like peptide-1 analog Exenatide, Liraglutide†, Albiglutide† Amylin analog Pramlintide Insulin analogs fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera) Dual PPAR agonists Aleglitazar†, Muraglitazar§, Tesaglitazar§ SGLT2 inhibitor Dapagliflozin†, Remogliflozin†, Sergliflozin† †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.